| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699371 | Clinical Oncology | 2009 | 7 Pages |
Abstract
Compared with patients receiving treatment, patients denied access to sunitinib and sorafenib had substantially worse survival outcomes, despite receiving treatment from the same clinical team. Access to the new drugs did not have an effect on overall use of National Health Service resources by funded patients. Modern treatments for advanced renal cancer should be available to all National Health Service patients with the disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N. James, J. Pascoe, A. Zachariah, D. Ray, A. Oldroyd, H. Parry, H. Benghiat, M. Karina, S. Collins, E. Porfiri,